# Franck Noiret

> Franck Noiret is a Series A investor at LBO France (Paris) backing Medical and Software. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [LBO France](https://shizune.co/investors/profile/lbo-france)
- Location: Paris, France
- Total investments: 5
- Last investment: Mar 2023
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/franck-noiret/0/905/81

Franck Noiret is a Series A investor at LBO France in Paris focused on Medical and Software. Franck Noiret - Managing Director - Venture Team @ LBO France

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 60% |
| Software | 2 | 40% |
| Biotechnology | 2 | 40% |
| Pharmaceutical | 2 | 40% |
| Eyewear | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Venture - Series Unknown | 2 | 40% |
| Funding Round | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 2 | 40% |
| United States | 1 | 20% |
| United Kingdom | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kayentis | Kayentis, SAS provides data and real-time information capture and collection solutions. It offers Digital Pen Paper (DPP) solutions for the clinical trial industry. The company also provides Clin'Form that allows data written using a DPP to be recorded in an information system and shared via a Web portal. It serves life sciences, finance, andmanufacturing markets. The company was incorporated in 2004 and is headquartered in Gif sur Yvette, France. | $2.4M | Venture - Series Unknown | Mar 28, 2023 |  |
| SiVIEW | SiVIEW specializes in providing IT solutions to find prescribed eyeglasses. | $5.5M | Series A | Sep 13, 2022 |  |
| Antidote.me | Antidote is a digital health company focused on accelerating and improving medical research. By combining proprietary technologies, data, and well-established business models, the company is transforming the way patients and researchers connect so that breakthroughs happen faster.Antidote was launched as TrialReach in 2010 and rebranded toAntidote in 2016. The company is based in the US and the UK. | $23.2M | Venture - Series Unknown | Jun 03, 2021 |  |
| Kayentis | Kayentis, SAS provides data and real-time information capture and collection solutions. It offers Digital Pen Paper (DPP) solutions for the clinical trial industry. The company also provides Clin'Form that allows data written using a DPP to be recorded in an information system and shared via a Web portal. It serves life sciences, finance, andmanufacturing markets. The company was incorporated in 2004 and is headquartered in Gif sur Yvette, France. | $7.7M |  | Dec 02, 2020 |  |
| Quantificare | Quantificare is set into motion an enterprising project based on twenty years of experience in medical imaging, with the aim of transforming pioneering ideas into innovative products and services. | $5.5M | Series A | Sep 05, 2019 |  |

5 of 5 investments shown.

## Co-investors
- [Extens](https://shizune.co/investors/profile/extens-2) — VC Fund, 3 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together
- [Merck Global Health Innovation Fund](https://shizune.co/investors/profile/merck-global-health-innovation-fund) — VC Fund, 1 deal together
- [Octopus Ventures](https://shizune.co/investors/profile/octopus-ventures) — VC Fund, 1 deal together
- [Smedvig Ventures](https://shizune.co/investors/profile/smedvig-capital) — VC Fund, 1 deal together

## About LBO France

VC Fund · Paris, France

LBO France is private equity firms in France.They offer exceptional coverage of the French market, with four interlocking areas of expertise: middle market buyouts (the White Knight funds), small cap buyouts (the Hexagone funds), real estate (the White Stone and Lapillus funds) and secondary debt (the Altercap funds). This breadth of specialistknowledge makes us a private equity leader in France – the second-largest economy in Europe and the fifth-largest in the world.With seasoned and diversified teams, a well-established position and in-depth knowledge of the French economy, LBO France offers management and investors of portfolio companies a wealth of experience and opportunities that spur value creation..Their strategy of diversification and growth has enabled us to achieve a critical mass that allows us to devote substantial financial and human resources to continuously improve the services they provide to their portfolio companies and investors.

5 contacts available at LBO France.

| Name | Title | Profile |
| --- | --- | --- |
| Franck Noiret | Managing Director - Venture Team | https://shizune.co/investors/profile/franck-noiret |
| Frederic Teboul | CFO Business Unit Venture | https://shizune.co/investors/profile/frdric-teboul |
| Jacques Franchi | Partner, Head of Debt and CIO | https://shizune.co/investors/profile/jacques-franchi |
| Jean-Marie Leroy | Partner | https://shizune.co/investors/profile/jean-marie-leroy |
| Marie-Astrid Auriol | Partner and CFO | https://shizune.co/investors/profile/marie-astrid-auriol |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Franck Noiret invest in?

Franck Noiret invests primarily in Medical, Software and Biotechnology startups, most often at Series A and Venture - Series Unknown stage. Most of the 5 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Franck Noiret last invest?

The most recent investment recorded for Franck Noiret closed in Mar 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co